monoclonal_2

Image credit: DOI: 10.1038/s41577-021-00542-xThe progress of COVID-19 therapies has seen remarkable strides, particularly in the development and application of antibody-based treatments. Early in the pandemic, the focus was on supportive care, but the rapid advancement in antibody therapies has sign

Muronomab (Orthoclone OKT3) made history as the first FDA-approved monoclonal antibody. Biointron reviews its impact on immunotherapy and antibody drug development.

This month heralded the release of groundbreaking news involving the monoclonal antibody tegoprubart, which facilitated the successful transplantation of a genetically edited pig kidney into a 62-year-old man grappling with end-stage kidney disease.

From hybridomas to recombinant platforms, antibody production has evolved. Biointron reveals ten insights into methods that ensure reliable supply and scientific progress.

Learn how advanced monoclonal antibody production techniques like cell line engineering, process optimization, and purification overcome scalability and yield challenges.

This week, exciting news came out that Eledon Pharmaceuticals’ tegoprubart was successfully used to aid the first-ever transplant of a genetically-edited pig kidney into a 62-year-old man with end-stage kidney disease. Tegoprubart is an investigational anti-CD40L antibody that has a high affinity for CD40 ligand. CD40L signaling plays an important role in adaptive and innate immune cell activation and function, and is therefore a target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.

Single B cell technology accelerates antibody discovery. Biointron demonstrates how this approach delivers potent candidates faster and with greater precision.

Image credit: DOI: 10.3390/cancers16040800 In recent decades, the landscape of therapeutic antibodies has undergone a rapid evolution, catalyzing breakthroughs in modern medicine. These antibodies, characterized by their precise targeting and minimal side effects

The nucleocapsid of a virus, which consists of the capsid enclosing the viral nucleic acid, can be a target for antibody therapies. When a virus infects a host, its nucleocapsid becomes exposed to the immune system, triggering the production of antibodies specific to proteins present on the nucleocapsid's surface, preventing the virus from entering host cells, disrupting its replication cycle, or marking it for destruction by other components of the immune system.

Antibodies defend against disease and power modern biotech. Biointron shares ten fascinating facts that highlight their versatility and impact in research and therapy.

From hybridoma to recombinant platforms, Biointron leads innovations in antibody production and engineering, enabling faster, more flexible, and reliable research solutions.

Antibody combination therapies involve the use of two or more antibodies together as a treatment strategy to enhance the therapeutic effect against diseases, such as cancer or infectious diseases. This approach aims to target different epitopes or antigens simultaneously, increasing the efficacy of the treatment by overcoming resistance mechanisms, reducing the likelihood of disease escape, and providing a broader range of action.

High-throughput antibody production changes the pace of biotech. Learn how automation and  Single B Cell Screening deliver thousands of antibodies with speed and quality.

Personalized antibody therapies bring precision to treatment. Biointron highlights how monoclonal antibodies and ADCs target cancer, IBD, and other diseases with improved outcomes.

Monoclonal antibodies fight antimicrobial resistance by targeting pathogens and complementing antibiotics. Learn how they expand the arsenal against AMR threats.